Amgen Inc. (AMGN) Given Consensus Rating of “Buy” by Brokerages

Shares of Amgen Inc. (NASDAQ:AMGN) have earned a consensus rating of “Buy” from the twenty-five analysts that are covering the stock, Marketbeat reports. Eleven investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $190.03.

AMGN has been the subject of several recent analyst reports. ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Mizuho reiterated a “buy” rating and issued a $195.00 target price on shares of Amgen in a research note on Sunday, July 9th. Morgan Stanley reiterated an “overweight” rating on shares of Amgen in a research note on Monday, July 10th. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 target price on shares of Amgen in a research note on Tuesday, July 11th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $189.00 target price on shares of Amgen in a research note on Friday, July 14th.

Amgen (NASDAQ:AMGN) traded down 0.70% during trading on Friday, hitting $175.28. The stock had a trading volume of 3,478,617 shares. Amgen has a 12-month low of $133.64 and a 12-month high of $191.10. The stock has a 50 day moving average price of $184.87 and a 200 day moving average price of $172.14. The company has a market capitalization of $127.90 billion, a price-to-earnings ratio of 15.97 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same period last year, the business posted $3.02 EPS. Amgen’s revenue was down .7% on a year-over-year basis. Equities research analysts forecast that Amgen will post $12.67 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be paid a $1.15 dividend. The ex-dividend date is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a yield of 2.62%. Amgen’s dividend payout ratio (DPR) is 41.63%.

Amgen declared that its Board of Directors has initiated a share repurchase plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.19% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Baker Ellis Asset Management LLC acquired a new stake in Amgen in the third quarter valued at approximately $108,000. TrimTabs Asset Management LLC boosted its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Finally, Phocas Financial Corp. acquired a new stake in Amgen in the second quarter valued at approximately $110,000. 78.09% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/10/29/amgen-inc-amgn-given-consensus-rating-of-buy-by-brokerages.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit